Boston Scientific named Johnson & Johnson alum Michael Mahoney CEO. Mahoney became president of Boston Scientific in October of last year and is replacing interim CEO William Kucheman, who will stay on as a consultant. The company said in a statement that Mahoney has overseen CRM regulatory approvals as well as the Cameron Health acquisition and increased the company’s focus on global expansion since joining the company last year. The company noted that Mahoney put off being named CEO to wait out post-employment obligations connected with his time at J&J. Mahoney’s experience also includes working as President and CEO of Global Healthcare Exchange and 12 years at General Electric Medical Systems.
Watson Pharmaceuticals has installed a Global Generics Management Team. The company announced the new team Thursday. President and CEO Paul Bisaro said in a statement the team will help the company “capitalize on the momentum” of the company since its April acquisition of Actavis. Andrew Boyer is leading the US generics business, which accounts for about 10% of the US market. Jean-Guy Goulet is the lead for the Canada and Latin American businesses and Lars Ramneborn is head of European generics. Siggi Olaffson is President of Global Generics.